STOCK TITAN

Nyxoah to Release First Half 2021 Financial Results on August 31 and Host Earnings Conference Call on September 1, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Nyxoah SA (Nasdaq: NYXH) announced its plan to release financial results for the first half of 2021 on August 31, 2021, after US markets close. A conference call will be held on September 1, 2021, at 3:00 p.m. CET to discuss these results. The company focuses on innovative solutions for treating Obstructive Sleep Apnea (OSA) and has made progress with its Genio® system, which received European CE Mark approval in 2019. Nyxoah is currently conducting pivotal studies for FDA approval and further research on the therapy's long-term efficacy.

Positive
  • Successful completion of BLAST OSA study supporting Genio® system.
  • Genio® system received European CE Mark in 2019.
  • Ongoing DREAM IDE pivotal study aiming for FDA approval.
Negative
  • None.

Mont-Saint-Guibert, Belgium. - August 11, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it will release financial results for the first half of 2021 on Tuesday, August 31, 2021, after the US markets close. Company management will host a conference call to discuss financial results on Wednesday, September 1, 2021, beginning at 3:00 p.m. CET / 9:00 a.m. ET.

Investors interested in listening to the conference call may do so by dialing (844) 260-3718 for US, 0800 73264 for Belgium, or (929) 517-0938 for international callers, followed by Conference ID: 7468474. A live and archived webcast of the event will be available on the Company’s investors relations website at https://investors.nyxoah.com/.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company has completed the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion and is currently conducting the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.

For more information, please visit http://www.nyxoah.com/.

Contacts:

Nyxoah
Fabian Suarez, Chief Financial Officer
corporate@nyxoah.com
+32 (0)10 22 24 55

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment


FAQ

When will Nyxoah release its financial results for H1 2021?

Nyxoah will release its financial results for the first half of 2021 on August 31, 2021, after US markets close.

What is the conference call schedule for Nyxoah's H1 2021 financial results?

The conference call to discuss H1 2021 financial results will be held on September 1, 2021, at 3:00 p.m. CET.

What is the Genio® system by Nyxoah?

The Genio® system is a hypoglossal neurostimulation therapy for treating Obstructive Sleep Apnea, which received CE Mark approval in 2019.

What studies is Nyxoah currently conducting?

Nyxoah is conducting the DREAM IDE pivotal study for FDA approval and the post-marketing EliSA study in Europe.

Nyxoah SA Ordinary Shares

NASDAQ:NYXH

NYXH Rankings

NYXH Latest News

NYXH Stock Data

408.33M
23.09M
38.32%
32.48%
0.25%
Medical Instruments & Supplies
Healthcare
Link
United States of America
Mont-Saint-Guibert